In recent decades, several advanced technologies, represented by continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems, have been implemented to improve the management of T1D, with the dual goals of achieving optimal glycemic control and reducing the incidence of acute complications such as secondary severe DKA and severe hypoglycemia [110,111]. This evidence concerns the gene INS and type 1 diabetes mellitus.